Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas von Gilardi, Mara, Wang, Zhiyong, Proietto, Marco, Chilla, Anastasia, Calleja-Valera, Juan Luis, Goto, Yusuke, Vanoni, Marco, Janes, Matthew R., Mikulski, Zbigniew, Gualberto, Antonio, Molinolo, Alfredo A., Ferrara, Napoleone, Gutkind, J. Silvio, Burrows, Francis

Volltext

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier von Di, Kaijun, Lloyd, G Kenneth, Abraham, Vivek, MacLaren, Ann, Burrows, Francis J, Desjardins, Annick, Trikha, Mohit, Bota, Daniela A

Volltext

Targeting multiple signal transduction pathways through inhibition of Hsp90 von HONG ZHANG, BURROWS, Francis

Volltext

CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target von Malik, Shivani, Westcott, Jill M, Brekken, Rolf A, Burrows, Francis J

Volltext

Therapeutic and diagnostic implications of Hsp90 activation von Kamal, Adeela, Boehm, Marcus F, Burrows, Francis J

Volltext

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors von Burrows, Francis J, Kamal, Adeela, Thao, Lia, Sensintaffar, John, Zhang, Lin, Boehm, Marcus F, Fritz, Lawrence C

Volltext

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients von Levin, Nancy, Spencer, Andrew, Harrison, Simon J., Chauhan, Dharminder, Burrows, Francis J., Anderson, Kenneth C., Reich, Steven D., Richardson, Paul G., Trikha, Mohit

Volltext

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation... von Rausch, Johanna, Dzama, Margarita M, Dolgikh, Nadezda, Stiller, Hanna L, Bohl, Stephan R, Lahrmann, Catharina, Kunz, Kerstin, Kessler, Linda, Echchannaoui, Hakim, Chen, Chun-Wei, Kindler, Thomas, Döhner, Konstanze, Burrows, Francis, Theobald, Matthias, Sasca, Daniel, Kühn, Michael W M

Volltext

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 von Lundgren, Karen, Zhang, Hong, Brekken, John, Huser, Nanni, Powell, Rachel E, Timple, Noel, Busch, David J, Neely, Laura, Sensintaffar, John L, Yang, Yong-ching, McKenzie, Andres, Friedman, Jessica, Scannevin, Robert, Kamal, Adeela, Hong, Kevin, Kasibhatla, Srinivas R, Boehm, Marcus F, Burrows, Francis J

Volltext

Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pan... von Zhang, Yuqing, Kirane, Amanda, Huang, Huocong, Sorrelle, Noah B, Burrows, Francis J, Dellinger, Michael T, Brekken, Rolf A

Volltext

The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins von Dickey, Chad A, Kamal, Adeela, Lundgren, Karen, Klosak, Natalia, Bailey, Rachel M, Dunmore, Judith, Ash, Peter, Shoraka, Sareh, Zlatkovic, Jelena, Eckman, Christopher B, Patterson, Cam, Dickson, Dennis W, Nahman, Jr, N Stanley, Hutton, Michael, Burrows, Francis, Petrucelli, Leonard

Volltext

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies von Figarol, Sarah, Delahaye, Célia, Gence, Rémi, Doussine, Aurélia, Cerapio, Juan Pablo, Brachais, Mathylda, Tardy, Claudine, Béry, Nicolas, Asslan, Raghda, Colinge, Jacques, Villemin, Jean-Philippe, Maraver, Antonio, Ferrer, Irene, Paz-Ares, Luis, Kessler, Linda, Burrows, Francis, Lajoie-Mazenc, Isabelle, Dongay, Vincent, Morin, Clara, Florent, Amélie, Pagano, Sandra, Taranchon-Clermont, Estelle, Casanova, Anne, Pradines, Anne, Mazieres, Julien, Favre, Gilles, Calvayrac, Olivier

Volltext

Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer von KIRANE, Amanda, TOOMBS, Jason E, OSTAPOFF, Katherine, CARBON, Juliet G, ZAKNOEN, Sara, BRAUNFELD, Jordan, SCHWARZ, Roderich E, BURROWS, Francis J, BREKKEN, Rolf A

Volltext

Hsp90 Activation and Cell Cycle Regulation von Burrows, Francis, Zhang, Hong, Kamal, Adeela

Volltext

Therapeutic potential of ERK5 targeting in triple negative breast cancer von Ortiz-Ruiz, María Jesús, Álvarez-Fernández, Stela, Parrott, Tracy, Zaknoen, Sara, Burrows, Francis J, Ocaña, Alberto, Pandiella, Atanasio, Esparís-Ogando, Azucena

Volltext

Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor von ALVAREZ-FERNANDEZ, Stela, ORTIZ-RUIZ, María Jesus, PARROTT, Tracy, ZAKNOEN, Sara, OCIO, Enrique M, SAN MIGUEL, Jesús, BURROWS, Francis J, ESPARIS-OGANDO, Azucena, PANDIELLA, Atanasio

Volltext

ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukem... von Castro, Januario E., Prada, Carlos E., Loria, Olivier, Kamal, Adeela, Chen, Liguang, Burrows, Francis J., Kipps, Thomas J.

Volltext

BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy von Yin, Xiaoying, Zhang, Hong, Lundgren, Karen, Wilson, Lynn, Burrows, Francis, Shores, Carol G.

Volltext

The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action von Chen, Rong, Tsai, Jennifer, Thompson, Philip A., Chen, Yuling, Xiong, Ping, Liu, Chaomei, Burrows, Francis, Sivina, Mariela, Burger, Jan A., Keating, Michael J., Wierda, William G., Plunkett, William

Volltext

Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity von BÖLL, Boris, ELTAIB, Farag, VON STRANDMANN, Elke Pogge, REINERS, Katrin S, VON TRESCKOW, Bastian, TAWADROS, Samir, SIMHADRI, Venkateswara R, BURROWS, Francis J, LUNDGREN, Karen, HANSEN, Hinrich P, ENGERT, Andreas

Volltext